enGene Therapeutics (ENGN) vs Outlook Therapeutics (OTLK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Outlook Therapeutics (OTLK) has outperformed enGene Therapeutics (ENGN) over the past year, losing 55.2% versus a loss of 76.0%. Outlook Therapeutics is the larger company by market cap ($137.3 million vs $119.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENGN | OTLK |
|---|---|---|
| Share price | $1.78 | $0.564 |
| Market cap | $119.29M | $137.30M |
| 1-day change | +2.01% | -4.41% |
| YTD return | -80.29% | -64.30% |
| 1-year return | -75.98% | -55.24% |
| 5-year return | — | -98.66% |
| EPS (TTM) | $-2.07 | $-0.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.25 | $2.54 |
| 52-week low | $1.40 | $0.161 |
| Distance from 52-week high | -85.47% | -77.78% |
| Analyst consensus | none | none |
| Avg. price target upside | +84.83% | +791.84% |
| Average volume | 746.58K | 13.33M |
| Shares outstanding | 67.02M | 243.45M |
| Employees | 81 | 17 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OTLK has outperformed ENGN by 20.7 percentage points over the past year.
- The two companies sit in different sectors: enGene Therapeutics in Healthcare and Outlook Therapeutics in Health Care.
About enGene Therapeutics
ENGN stock →enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer.
Healthcare · Biotechnology · 81 employees
About Outlook Therapeutics
OTLK stock →Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17 employees
ENGN vs OTLK FAQ
Which is bigger, enGene Therapeutics or Outlook Therapeutics?
Outlook Therapeutics (OTLK) is larger, with a market capitalization of $137.30M compared with $119.29M for enGene Therapeutics (ENGN).
Which stock has performed better over the past year, ENGN or OTLK?
OTLK returned -55.24% over the past 12 months, compared with -75.98% for ENGN (price return, excluding dividends). Past performance does not predict future results.
Are enGene Therapeutics and Outlook Therapeutics in the same industry?
No. enGene Therapeutics is in the Healthcare sector, while Outlook Therapeutics is in Health Care.